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ABSTRACT 
Background 
Novel antimicrobial treatments are urgently needed. Previous work has shown that the mucus of the 
brown garden snail (Cornu aspersum) has antimicrobial properties, in particular against type culture 
collection strains of Pseudomonas aeruginosa.  We hypothesised that it would also be effective 
against clinical isolates of the bacterium and that investigation of fractions of the mucus would 
identify one or more proteins with anti-pseudomonal properties, which could be further 
characterised.  
Materials and methods: Mucus was extracted from snails collected from the wild. Antimicrobial 
activity against laboratory and clinical isolates of Ps.  aeruginosa was determined in disc diffusion 
assays. Mucus was purified using size exclusion chromatography and fractions containing anti-
pseudomonal activity identified.  Mass spectroscopy and high performance liquid chromatography 
analysis of these fractions yielded partial peptide sequences. These were used to interrogate an RNA 
transcriptome generated from whole snails. 
Results: Mucus from C. aspersum inhibited growth of type collection strains and clinical isolates of 
Ps. aeruginosa. Four novel C. aspersum proteins were identified; at least three are likely to have 
antimicrobial properties. The most interesting is a 37.4 kDa protein whilst smaller proteins, one 17.5 
kDa and one 18.6 kDa also appear to have activity against Ps. aeruginosa. 
Conclusions: The study has identified novel proteins with antimicrobial properties which could be 
used to develop treatments for use in human medicine. 
 
Key words: antimicrobial; transcriptome; lectin; mucus; Cornu aspersum, Pseudomonas aeruginosa, 
transcriptome 
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Introduction   
Antimicrobial resistance is a major public health problem [1] and scientists and clinicians 
need to devise protocols that encourage more efficient and sparing use of antimicrobial 
agents [2, 3] in order to limit this. Multidrug resistant strains of many important pathogens, 
including Pseudomonas aeruginosa have emerged [4]. Thus, there is a requirement to 
develop new antimicrobial agents. One approach is to investigate mechanisms of resistance 
and thereby design drugs that can overcome them [5]. Another is to explore the reliability of 
accounts of the effectiveness of natural remedies.  This has yielded some significant 
outcomes including the development of artemisinin to treat chloroquine–resistant strains of 
the malaria parasite Plasmodium spp. [6] and tea tree oil for skin infections [7].   
Ps .aeruginosa is an opportunistic pathogen in humans; it is associated with a range of 
clinical presentations, including lower respiratory tract infections, septicaemia, wound 
infections and ear infections [8]. Nosocomial acquisition is a risk, especially in 
immunocompromised patients and those with severe burns [9]. Patients with cystic fibrosis 
are especially susceptible to respiratory infections with Ps. aeruginosa. Infection can be 
intractable, since the bacteria form biofilms within the lungs which antibiotics cannot fully 
penetrate [10]. Multidrug resistant and extreme multidrug resistant strains of Ps. 
aeruginosa are of increasing concern [8, 10]. The bacterium is ubiquitous in the 
environment and pseudomonal infections are found in vertebrates, invertebrates and plants 
[11, 12]. Therefore, the strategies different organisms employ for defence against Ps. 
aeruginosa might be a source of naturally occurring antimicrobial agents, which could be 
used in human medicine.    
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The common brown garden snail, Cornu aspersum (Helix aspersa) has been valued for its 
healing properties since ancient times [13]. Snail-based remedies have been advocated for 
the treatment gastrointestinal and respiratory conditions, infections characterised by rashes 
(including measles and smallpox), hernias and skin lesions [13]. Terrestrial molluscs secrete 
mucus, which is a viscous and biochemically complex substance. It facilitates locomotion, 
helps reduce water loss, acts as a defence against predators and its components enable 
communication between snails of the same species [14].  Among the constituents of snail 
mucus are glycoproteins, some of which are lectins with agglutination properties [15].  
Cosmetic preparations containing extracts of C. aspersum mucus are currently widely 
marketed for the reduction of wrinkles and scarring [16, 17]. However, mucus extracts also 
promote healing of burn wounds [18] and preliminary work indicates that they have anti-
tumour properties and might have promise for treating melanogenesis [19]. To date, there 
have been few studies on the antimicrobial properties of the mucus of terrestrial molluscs 
[20] and most workers have focussed on the African Giant Land snail, Achatina fulica. Its 
mucus contains a 160 kDa glycoprotein ‘achacin’, which displays fairly broad-spectrum 
antimicrobial properties [20, 21, 22, 23] and a 9 kDa antimicrobial peptide [24].  C. aspersum 
mucus also has antimicrobial activity, attributable to one or more proteins between 30 and 
100 kDa in size [25, 26]. There are two candidate proteins in this range – one approximately 
50 kDa [25, 26] and the other estimated as between 30 and 40 kDa [25] or 41 kDa [26].  
In previous studies, preparations of C. aspersum mucus exhibited very clear activity against 
several laboratory-adapted culture collection strains of Ps. aeruginosa [26]. To investigate 
whether C. aspersum contains any  antimicrobial agents which would be clinically useful, 
tests against  isolates from patients are required. Testing of Ps.aeruginosa strains obtained 
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from patients with cystic fibrosis would be the logical place to start this work. In addition, 
development of any such product requires identification and characterisation of the protein 
(s) responsible for the observed effects.   
Therefore, the hypothesis for this present study was: C.aspersum mucus contains one or 
more proteins that have antimicrobial activity against Ps.aeruginosa  
 
 Materials and methods  
Twenty Cornu aspersum snails were collected from the wild in East Sussex, UK . They were 
placed in clear plastic tanks, part-filled with moist coconut husk substrate. These were kept 
in a room with ambient light and average temperature of 20 °C. The snails were fed 
cucumber, butternut squash, green peppers, lettuce, and carrots and a provided with a 
source of calcium. 
Mucus was collected by stimulating the snails with a cotton swab moistened in phosphate 
buffered saline (PBS) as described previously [25]. Mucus was harvested using a 5mL plastic 
Pasteur pipette and, after settling at room temperature for 1-2 hours, placed into a 20mL 
sterile plastic bijou bottle and diluted approximately 1:2 with PBS. The preparation method 
was modified to include an additional step of placing  2-4  8mm glass beads into the bijou 
before shaking overnight (18-20 hours) at 4 °C. The shaken mucus was centrifuged at 4000 
rpm for 20 minutes to sediment large debris. The resulting supernatant was passed through 
a 0.45 micron filter after which its protein content was determined using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, East Grinstead, West Sussex, UK) and found to be 
between 4.0 and 8.0mg/ mL  (n=4). 
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As required, size separation was carried out in Vivaspin 500 columns (Sartorius Stedim Lab 
Ltd, Stonehouse, Gloucestershire, UK) at 1,000 kDa , 100 kDa, 30 kDa. The filtrate from the 
1,000 kDa column was used to eliminate larger proteins. The 100 kDa and 30 kDa separation 
columns were used to concentrate the mucus fraction containing proteins between those 
two sizes, since previous work [25] had identified the active ingredient in C. aspersum to be 
in that size band.  
 
Antimicrobial testing was as follows. Mucus was tested for anti-microbial activity against Ps. 
aeruginosa NCIMB 10548,   Ps. aeruginosa NCTC 10662 and  five well characterised clinical 
isolates of Ps. aeruginosa . These were isolates 2, 9, 10, 34 and 43 from the panel compiled 
by De Soyza et al.  [27], which all originated from patients with cystic fibrosis.   Disc diffusion 
assays were undertaken as previously described [26] using overnight Tryptone Soy Broth 
(Oxoid, Basingstoke, Hampshire, UK) cultures, diluted in PBS to between 106 and 107  colony 
forming units (cfu) per mL (verified by viable count). Aliquots of 100 L were placed onto 
Isosensitest agar (ISA; Oxoid) plates and left to dry for 15 minutes. Then between three and 
six 5mm sterile assay discs were placed on the plates and 50 L of prepared mucus added to 
each disc. Every plate set up included a PBS control disc. Plates were left to dry for a further 
40-60 minutes before incubation overnight (18-20 hours), aerobically at 37 °C. Zones of 
inhibition were recorded in mm. A minimum of three replicates was tested against a 
particular strain of bacterium, but in most cases it was more than six.  
 
For Size Exclusion Chromatography (SEC), prepared C. aspersum mucus was loaded on to a 
Superdex 75 16/60 column (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, 
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UK), previously equilibrated with PBS. The column was run at 1 mL/min and fractions of 1.5 
mL were collected. These fractions were submitted to SDS-PAGE and those showing the 
same protein pattern were pooled, concentrated using a 5 kDa cut -off Millipore spin filter 
and analysed by SDS-PAGE. Two proteins which appeared to be present in high 
concentrations were cut out from the gel and sent for analysis by Mass Spectroscopy.  
This experiment was repeated using a Superdex 75 26/60 column (GE Healthcare Life 
Scientific), with the column run at 2 ml/min and fractions of 2 ml. The elution profile, 
monitored at 280nm showed several peaks. Eluted fractions were bulked into pools 
(labelled 1-6), based on protein pattern. Five of the resulting pools (2 to 6) were tested in 
duplicate against Ps. aeruginosa NCIMB 10548 in the disc diffusion assay described above 
and they were also examined by SDS-PAGE. One of the proteins observed was excised from 
the gel and analysed further by HPLC – chromatogram sequencing.  
Proteins selected for further analysis by mass spectrometry were separated using SDS-PAGE 
taking account of precautions to minimise keratin contamination. The resulting gel was sent 
to  the Centre of Excellence for Mass Spectrometry, King’s College London. Two proteins 
from the SDS-PAGE were selected for MS analysis, one of approximately 50 kDa and the 
other estimated to be between 17 and 18 kDa in size. Selected proteins were excised from 
the gel and de-stained then reduced (with dithiothreitol {DTT}), treated with iodoacetamide 
(to alkylate any free cysteine residues) and digested overnight with trypsin.  The resulting 
peptide fragments were washed and then lyophilised after which they were re-suspended in 
50mM ammonium bicarbonate. The suspensions were then subjected to reverse phase 
chromatography in an EASY NanoLC (Thermo Scientific) Ultra HPLC analyser and the eluted 
peptides ionised by electrospray and fragmented in an Orbitrap Velos Pro using collision-
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
This script OK’d by ADB 3/4/19 
8 
 
induced dissociation. The 20 ions that registered most strongly were analysed in the 
Proteome Discover V1.4 software and compared to peptide sequences in the Uniprot 
database. The data were also analysed with the PEAKS mass spectrometry software. 
Resulting peptides were compared with sequences in a Helix pomatia database (New 
England Biolabs, MA, USA). 
 
For HPLC-chromatogram sequencing, prepared mucus was concentrated by passing it 
through 1MDa and 100 kDa Vivaspin 500 columns (Sartorius) and running out in an SDS-
PAGE gel. The fraction of interest (30-40 kDa) was cut and sent to The Proteome Factory AG, 
Berlin, Germany, where sequencing analysis was undertaken by Ms Julia Schendel. Using 
HPLC–chromatogram analysis a series of peptides was obtained after digestion with trypsin, 
chymotrypsin, elastase and LysC.  
 
For RNA transcriptome sequencing, individual C. aspersum snails were stimulated to 
produce mucus as described above and then snap frozen in liquid nitrogen. After freezing, 
the shell was broken off and the body ground to a paste in a pestle and mortar; the pestle 
and mortar were kept cold throughout this process. Total RNA was extracted using the 
E.Z.N.A.(r) Mollusc RNA Kit (Omega BIO-TEK, Norcross, USA.),  following the manufacturer’s 
instructions for the long protocol. Total RNA was quantified for purity and integrity by UV-
Vis spectroscopy (NanoDrop, Thermoscientific, Waltham, Massachusetts, USA. Samples 
were then stored at -80oC before transport to The University of Liverpool, Centre for 
Genomic Research. RNA was further purified using an RNA Clean & Concentrator kit (Zymo 
Research, California,USA) and total RNA quantified using a 2100 Agilent Bioanalyzer (RNA 
Nanochip, Agilent Technologies, Waldbronn, Germany).    
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
This script OK’d by ADB 3/4/19 
9 
 
The sample was treated with a Teloprime full length cDNA amplification kit (Lexogen GmbH, 
Vienna, Austria) following the manufacturer’s protocol. The product was checked for 
concentration and profile using a bioanalyser high sensitivity chip.  
The ends of the sample were damage and end repaired using the Template preparation kit 
(Pacific Biosciences, California, USA). After cleaning with Ampure XP beads (Beckman 
Coulter, Indiana, USA), the sample was ligated to PB adapter overnight at 25°C. The 
SMRTbell library was treated with exonuclease to remove non circular DNA. The SMRTbell 
library was cleaned and this was used to load sequel cells using diffusion loading at 6pM on 
plate concentration and a 2 hour pre extension. 
The resulting PacBio READS where analysed at the   University of Liverpool, Centre for 
Genomic Research using the ISO-seq pipeline (SMRT link software 5.0.1.9585) with the 
default parameter settings. The transcriptome was annotated using TransDecoder (version 
3.0.1) for each strand and protein sequences were annotated using BLASTp (National Center 
for Biotechnology Information [NCBI], Bethesda, MD;http://www.ncbi.nlm.nih.gov/BLAST/). 
Protein sequences with a blast e-val below 0.01 were selected as best match.  
The transcriptome was probed using the peptide sequences obtained from Mass 
Spectroscopy and HPLC using BLASTn. Matches to transcripts were further analysed using 
the EXPASY translate tool (https://web.expasy.org/translate/) to search for open reading 
frames. Proteins found to match to the relevant peptides were subjected to analysis using 
BLASTp.  
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Results 
For antimicrobial spectrum of activity in C. aspersum mucus, zones of inhibition were 
observed in all cases when the mucus was tested against the laboratory strains and clinical 
isolates of Ps. aeruginosa. Figure 1 is an example of an anti-microbial disc diffusion assay 
plate where mucus was tested against Ps.aeruginosa NCIMB 10548.  It shows a very narrow 
zone of clearing (<0.1mm) around the PBS control and obvious zones of inhibition around 
the three control discs. The mean zones of inhibition recorded for the culture collection and 
clinical isolates of Ps.aeruginosa were all between 9 and 13mm.    
 
Size exclusion chromatography of C. aspersum mucus proteins was as follows. During the 
first Superdex column run, two peaks were eluted. Although one of these peaks appeared to 
represent three distinct protein fractions, they all showed similar protein patterns on SDS-
PAGE. One of these fractions (A) is shown in Figure 2a, along with the proteins from the 
second peak (B). There were strongly staining bands at approximately 50 kDa and 17 kDa 
and these two bands were sent for Mass Spectroscopy.  
 
Figure 2b shows the trace obtained from the second SEC procedure; the peaks are labelled 1 
to 6, where 1 contains the protein aggregates. Figure 2c is the SDS-PAGE gel carried out on 
the fractions on the day of the SEC experiments, indicating the proteins detected in each 
fraction. Table 1 shows the estimated sizes of the proteins detected in each fraction and 
which ones were found to have antibacterial activity.  
 
Peptides identified in C. aspersum mucus from mass spectrometry analysis and HPLC-
chromatographic analysis were as follows. From the first SEC experiment the ~17 kDda and 
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the ~50 kDa proteins (indicated in Figure 2a) were selected for Mass Spectrometry analysis. 
Table 2 shows the putative peptides obtained after deduction in comparison with a H. 
pomatia database.  After the antimicrobial analysis of the fractions from the second SEC 
(Table 2), the protein of approximately 39 kDa was sent for the HPLC-chromatographic 
analysis; the peptides obtained from this are also shown in Table 2. Using these peptides to 
probe the transcriptome database, four proteins were identified, as indicated in Table 2.   
 
Transcriptome sequencing and assembly were as follows. Using the peptide sequences 
(Table 2) to probe the proteins identified in the RNA transcriptome revealed that peptide 1 
aligned to a single match in the transcriptome. This sequence had 4 open reading frames, 
the longest of which is a protein sequence of 159 amino acids (17.5 kDa) (protein 1), (Figure 
3). Protein 1 contains a conserved region of the complement Cq1 superfamily. Protein 1 has 
been submitted to the NCBI GenBank and allocated the accession number MK393387. 
A combination of peptides 3,5 and 6 matched to a 583 amino acid protein (64 kDa) that was 
identified as protein 2 (Figure 3).   
Peptide 11 matched to a 169 amino acid protein (18.6 kDa) (Figure 3) that was identified as 
protein 3. Amino acids 1- 155 map to a conserved region in the fibrinogen related domain 
(FReD) superfamily. Protein 3 has been submitted to the NCBI GenBank and allocated the 
accession number MK393388. 
 
A combination of peptides 12, 13, 14, 15,16, 17 and 18 matched to a protein of 340 amino 
acids in length (37.4 kDa), labelled protein 4 (Figure 3). This sequence appeared in three 
separate places in the transcriptome. Two of these sequences have been submitted to the 
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NBCI GenBank and allocated the accession numbers MK393385 and MK393386. Amino acids 
150 to 340 map to a conserved region from the von Willebrand Factor A superfamily.  
 
Discussion  
This study has confirmed the findings of Pitt et al. [25] and Bortolotti et al. [26] that C. 
aspersum mucus contains one or more proteins with anti-microbial activity against Ps. 
aeruginosa. The results for the antimicrobial plate assay were essentially qualitative, since 
the concentration of the active ingredient(s) within the mucus was not known. 
Nevertheless, clear and reproducible zones of inhibition were obtained not only with the 
type culture collection strains, but with all five clinical isolates which came from patients 
with cystic fibrosis.      
This is an important finding as it indicates that further characterisation of the active 
ingredient(s) is justified. Previous work on C. aspersum mucus identified two possible 
proteins in the size range of between 30 kDa and 100 kDa on SDS-PAGE with anti-microbial 
activity against Ps. aeruginosa [25, 26] and this was confirmed by repeated plate assays (S. 
Pitt, unpublished data) and Minimum Inhibitory Concentration experiments (J. Hawthorne, 
unpublished data). One of the proteins is between 50 and 60 kDa and the other between 30 
and 40 kDa. Analysis by SDS-PAGE of the fractions of mucus obtained by the SEC procedure 
revealed proteins that corresponded with these sizes (Figures 2a and 2c). In addition, the 
SDS-PAGE of the unfractionated mucus showed clear bands in the 10-20 kDa size regions 
(Figures 2a and 2b). Some or all of these are likely to be lectins, which are common 
components of gastropod mucus. There are various classes of lectins and some of them 
function in the invertebrate immune response [28, 29]. Lectins also play a role in mollusc 
mucus function, including binding /attaching to substrates and contributing to viscosity. 
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They have also been found to have unexpected properties with respect to binding 
mammalian cells. For example, C. aspersum mucus extracts promote wound healing by 
stimulating the proliferation and migration of mammalian fibroblasts [30]. Similarly, the 
ability of the H. pomatia agglutinin (HPA) to attach to mammalian cells expressing the N-
acetylgalactosamine surface protein, which is a marker of malignancy. A 12 kDa lectin with 
similar properties is present within C. aspersum mucus. It binds to very specific mammalian 
cell surface markers and has been extensively characterised with a view to using it in 
diagnostic assays for cancers and other conditions [15].  
Previous size separation experiments with C. aspersum mucus found that component 
proteins less than 30kDa in size did not appear to express antimicrobial activity [25]. 
Therefore, the identification of a 17.5 kDa protein (‘protein 1’) with possible anti-microbial 
activity (Table 1, Table 2,  Figure 3) which appears to be a sialic acid binding lectin was an 
unexpected finding (Figure 6a). Some lectins have pathogen recognition receptor (PRR) 
properties [30] and this could contribute to the anti-microbial activity. Gastropod lectins 
have been known about for some time but to date none have been exploited for anti-
microbial treatments. Another unexpected finding was the 18.6 kDa protein (‘protein 3’) 
within the 30-40 kDa  mucus fraction ( Table 2, Figure 3, Figure 4c). The sequence suggests 
that it has a region consistent with the fibrinogen related domain (FreD). While fibrinogens 
are well known and characterised in mammals for their role in coagulation, they are also 
part of the invertebrate defence mechanism. FReDs work as part of the internal immune 
system and they have agglutination and lectin-like binding properties [31]. However, some 
FReDs with PRR and bacteriolytic properties – at least in vitro – are present in animals 
including shrimp [32] and amphioxus [33]. Although the presence of the 18.6 kDa protein in 
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the anti-pseudomonal fraction of the mucus noted here could be co-incidental, this might 
equally play an important function in the observed anti-bacterial effect.  
The initial SEC experiments suggested that the protein of around 50 kDa was present in 
large concentrations.  It was therefore selected for sequencing by mass spectroscopy. The 
second SEC and testing of the fractions against Ps. aeruginosa indicated that this protein 
probably lacks antimicrobial activity. As Table 1 shows, the 50 kDa protein was present in 
fractions 3, 4 and 5, although only the first and last of these showed antibacterial activity. 
Probing of the RNA transcriptome with the resulting peptides revealed a slightly larger 
protein of 64 kDa, ‘protein 2’ (Table 2, Figure 3). It remains unclear whether this is the 
protein identified as 50 kDa in the first SEC experiment. Protein 2 seems likely to be an 
extracellular matrix protein. 
Strong anti-pseudomonal activity was observed with fraction 6 (Table 1) which contained 
the protein between 30 and 40 kDa. The work following this up has identified a 37.4 kDa 
protein, ‘protein 4’ (Table 2, Figure 3). It was found in three separate places in the 
transcriptome, which suggests it is important for the snail. Reports of proteins in this mass 
range within invertebrates are limited, but they function as part of the mammalian innate 
immune response and some have anti-microbial properties. For example, cathelicidin LL-37 
has activity against E. coli, Candida albicans and Staph. aureus [34]. Another protein, CAP-37 
[35] appears to target Gram negative bacteria and has a particularly strong effect on Ps. 
aeruginosa.  The 37.4 kDa protein in C. aspersum mucus shares homology with a predicted 
collagen 6 (IV) protein in another species of snail, Biomphalaria glabrata, and a match to 
conserved domains of the von Willebrand factor A superfamily. Although it is an 
extracellular matrix protein, collagen 6(IV) from mammals has antibacterial properties and 
the significance of the vWFA domains in this effect was recently demonstrated [36].  
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Peptides containing the relevant domains are reported to have good activity against 
selected bacteria, including Ps.aeruginosa. This may provide a partial explanation for the 
antimicrobial properties of this novel protein, although BLAST results showed mapping to 
only 55% of the B. glabrata protein. 
The reason for the presence of a substance with targeted anti-pseudomonal activity in C. 
aspersum mucus is not immediately clear. Although Ps.aeruginosa is a common soil 
organism, to which terrestrial snails are continually exposed, there are many other potential 
pathogens in the soil environment. Ps. aeruginosa is a known pathogen of insects, within 
which it employs similar virulence factors to those in mammalian hosts [37]. Pseudomonas 
spp. thrive in the environmental conditions provided by human mucus, especially in the 
lungs of patients with cystic fibrosis [10, 38]. It is therefore possible that snail mucus has 
similar constituents that can enhance the growth of these bacteria, which necessitates 
specific protection.  Also, a specific immunological interaction between this particular 
mollusc and bacterium has been previously noted. Repeated injection with suspensions 
containing high titres of Ps. aeruginosa have been shown to stimulate a measurable immune 
response in C. aspersum, while preparations containing other microorganisms did not [39]. 
Thus, it appears that the anti-microbial proteins identified here could have a particular 
function in contributing to protection of C. aspersum against Ps.aeruginosa infections. If this 
could be ascertained, it may be possible to exploit it for development of treatment of 
human infections with this bacterium. As the results presented here indicate there appears 
to be promise for these proteins as treatment against Ps.aeruginosa strains implicated in 
serious respiratory infections, but they could also be used to in preparations to target 
infections in deep wounds . Therefore ,further characterisation of the form and function of 
all these proteins would be beneficial. Production of purified versions of the proteins would 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
This script OK’d by ADB 3/4/19 
16 
 
make them available in greater concentration than has been possible from crude mucus 
preparations. This would allow quantitative antimicrobial assays to be conducted as 
opposed to the qualitative results presented here. Re-investigation of the antimicrobial 
activity to confirm the specificity against Ps. aeruginosa could be conducted.  Detailed 
observations of the site within the bacterial cell and mechanism of action of each of these 
proteins could be carried out.  
Although four novel proteins have been identified here, the 37.4 kDa protein, to be named 
Aspernin, appears to be the most significant finding and it could be exploited to develop an 
antimicrobial substance for use in human medicine. Because C.  aspersum is farmed 
commercially in several countries, it is already possible to source large numbers of snails at 
low cost. Therefore, unlike many naturally-derived pharmaceutical compounds, sourcing the 
raw material would not be a problem and the antimicrobial components might be separated 
out when the snails are processed for other purposes. This work represents an advance in 
biomedical science because it has identified a potential novel antimicrobial treatment 
against the clinical important pathogen Ps. aeruginosa. 
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Summary table 
What is known about this subject 
 Cornu aspersum mucus has anti-microbial properties 
 It is particularly effective against Pseudomonas aeruginosa 
 The antimicrobial effect is attributable to one or more proteins between 30 and 
100kDa in size 
What this paper adds 
 Cornu aspersum mucus contains several proteins with anti-microbial properties 
 Three such proteins have been identified with masses of 17.5 kDa , 18.6 kDa and 37 
kDa respectively, the most important of these is the 37kDa protein , Aspernin 
 The mucus is effective against both type culture collection and clinical isolates of Ps. 
aeruginosa 
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Figure 1. Antimicrobial disc diffusion plate assays using Cornu aspersum mucus 
demonstrating  inhibition of Pseudomonas aeruginosa NCIMB 10548. Mucus preparations 
were tested in triplicate. P = phosphate buffered saline control.   
 
 
Figure 1. Antimicrobial disc diffusion plate assays using Cornu
aspersum mucus demonstrating  inhibition of Pseudomonas
 Figure 2a: SDS PAGE analysis of the protein profile of two of pooled fractions ( A and B) from 
the initial Superdex 16/60 run, showing strongly staining bands at 50 kDa  and 17 kDa in 
Fraction A.   
Molecular weight ladder is on the left hand side 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 2a, b and c
Figure 2b : Trace showing of fractions collected after running the mucus through a Superdex 75 26/60 
column    
 
Figure 2c: SDS-PAGE analysis of proteins in peaks 2-6 from Figure 2b. Molecular weight 
ladder is on the right hand side 
 
 
 
 
 
  
 
 
 
 
 
 
 Figure 3: Protein sequences 1-4  peptide sequences are highlighted  
 
 
 
Protein 1 MSLAIFVGVAIYAAAAAAQEFIGNVAFTAAFTEDTSVAEGRLVQYPVVFTNHGSGYNSNTGIFIATKGGLYVFHIHGQPTAGNDFSLTLYHNDNPIITASGRQQGDNVGTGSNSVTLRLKKNDRVSVKADIRSSLRGSSDSVFSTFSGYLIGLLTSSEL 
 
Protein 2 AVVCCSYMLREKMVALHLLLMALSAVAVIDGHYGRRGGGYRGGHGGGYLPGGRPHGGGRYGGGYYGGRPYGGHHGRPHYGFRGYGGAGGYVYTHGHAGGGFIGAVVDPYGWCQQTNDHGHSTGKVEKCPAIADIIVLLDTSSSMSRQEFELERNFAALLTEHFNVASGGVRFGAV
TFSDRVYESFNLASYSSNEAVKTAFRNTAYLAGGTKTYLALDYIRVNRLFSTSRGARDKSSKIVIVLTDGYSDSRSATKYAADALKNTGVKVISVGIGGSLGEELRNMASDGSLVFSADTFQSLTRIEQRVAASICSIPESEGYVPPTDEGKGDTKTCQEGFKPNPRNPSTCIDIDECQTNNPCQQT
CVNLPGSVRCTCKADFVINPKDTTKCNALRQCNDLVDIVFLVDESGSIGADNFKLQQTFVAKLTQHFNVGSNGARFAGVQFATQVKKLFDLNKYSSSKDISSALLGTPYGEGGTNTHLGLNYIADNKLFSTASGGRSNAPDVVIVVTDGESARPEQTKQAADRLKQQGATVVSVGVGDQVK
TSELIDIASSKDDVFVVSDFDLLDYIEENLTERICPSTRS 
 
Protein 3 IERRVSDDVDFKRTWADYKKGFGSVDSSYFIGLEPLHLLSDLGFNELRIDFKVDDKTYYAHYDVFKVGGEDAYYKLNVKDYSGDAGDSFSYYDGAVFSTSDSDHDADAKNCADISGGGGWWYKDCLAGLNGVYGHVTPDGIYWKTLNLKKPIQYLEMKVRNPNYEQGYN 
 
Protein 4 MNRRFICGVLLVVVSVTTISQGERFVFSATPITISPGVTPELTVRCGLEDDGNSGVSRVNSIIIRTVDGSVQKEVARIAYSQAAKGGFSTERASVTGDLSNKAGYLQITWPSPIHGLAGQYNCDIAALATVGDIVTFKSSMRVISTGFRQCYELVDIVFLVDESSSIGAVNFKLLQTFLANVTQHFK
VGSNGARFAGVQFATQVKKLFDLNKYSSSKDISSALLGTPYGQGSTYTHLGLNYIADNKLFSAASGGRSNAPDVVIVFTDGESTMPEQTKQAADRLKQQGATVVSVGVGGQFKTSELFDIASSKDAVFVVSDFNLLYYIENNLTARVCPSTRS 
 
Figure 3: Protein sequences 1-4  peptide sequences are highlighted 
Table 1: Characteristics of each peak from Figure 2b in terms of activity against Ps. 
aeruginosa  
NCIMB 10548 and sizes of the proteins in each peak as determined by SDS-PAGE  
 
Peak Mean zone of inhibition, mm Protein sizes, kDa 
2 0 250, 116, 72 
3 14 56, 50,17,15, 12 
4 0 60,50,23, 20,13 
5 12 50, 24, 20, 17, 14 
6 14.5 39, 12, 10, 5  
 
Table 1: Characteristics of each peak from Figure 2b in terms of
activity against Ps. aeruginosa
Table 2: Peptides obtained from the 17kDa, 50kDa and 30-40kDa proteins the matches in the 
transcriptome    
Peptide Putative protein 
from Mass 
Spectrometry (MS)/ 
HPLC-
chromatogram 
(HPLC)  
Sequence Match to 
transcriptome 
database 
1 17 kDa (MS) LGNVAFTAAFTEDTSVAEGR Protein 1 
2 17 kDa (MS) ANLLSGLLKTVVGLVGGLVKGDEVYVK No match 
3 50 kDa (MS) GTYLALDYL Protein 2 
4 50 kDa(MS) WWLVnLLmLVnESGSLGPPK Protein 2 
5 50 kDa(MS) WWLVDLLFLVDESGSLGPPK Protein 2 
6 50 kDa(MS) FGAVTFSDR Protein 2 
7 50 kDa(MS) VFDWGVTTLNK No match 
8 50 kDa(MS) LVLVTDGNSDSFLTNAAANLQK No match 
9 30-40 kDa (HPLC) VVCGTWWDTLMYR No match 
10 30-40 kDa(HPLC) QYLQVTWSSPR No match 
11 30-40 kDa(HPLC) VGGEDAYYK Protein 3  
12 30-40 kDa(HPLC) TNLGGLSSVHNEEGVVSCR Protein 4  
13 30-40 kDa(HPLC) ATVGDLVKF Protein 4  
14 30-40 kDa(HPLC) KLAKVF Protein 4  
15 30-40 kDa ATAGDLVKF  Protein 4  
16 30-40 kDa TAGDLVKF Protein 4  
17 30-40 kDa CGLEDEGLTGVSR Protein 4  
18 30-40 kDa DVANTKNLRY Protein 4  
 
Table 2: Peptides obtained from the 17kDa, 50kDa and 30-
40kDa proteins the matches in the transcriptome
